What's next for psychedelics after MDMA rejection?
Level 5 - mechanism / opinion, no new human data
News article providing journalistic commentary without original empirical data
PubMed 39146407 · doi:10.1126/science.ads4470
What was done
This is a news report discussing the regulatory rejection of Lykos Therapeutics' application for MDMA-assisted therapy for post-traumatic stress disorder (PTSD) by the US FDA and its implications for the psychedelic drug development sector.
What was found
The abstract reports no quantitative data or empirical findings. It notes that the regulatory rejection may drive a strategic shift among competitors in the psychedelic medicine field.
Why it matters
Highlights the regulatory and strategic landscape facing psychedelic drug development following a major regulatory setback for MDMA.
Limits
This publication is a news report rather than an original research study or systematic review. The abstract provides no clinical trial data, sample sizes, or quantitative endpoints.
Cited by
- supports The FDA initially denied approval for MDMA-assisted therapy in the summer of 2024.